AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01714284 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Informative
Description: The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
Study NCT01714284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
Study NCT05549687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05549687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05549687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Participate in Pack Health, an electronic support program
Study NCT05549687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Access to telephone triage line for support care services
Study NCT01596127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Rituximab
Description: Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I.
Study NCT03236805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
Study NCT03236805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
Study NCT03150888 — intervention group
Intervention type: DRUG
Intervention: Antihypertensive Agents
Description: Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
Study NCT03150888 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular risk factors
Description: Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
Study NCT04652999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation with Guided Imagery
Description: Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
Study NCT04652999 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Guided Imagery
Description: This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
Study NCT00233168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Program
Description: 14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
Study NCT00233168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Skills and Self-Esteem Training Program (Attention Control Arm)
Description: Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
Study NCT01883375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Talk
Description: Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
Study NCT01883375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Dignity Talk Communication Topics
Description: There have not been any non-completers - this arm not being used currently
Study NCT01723280 — intervention group
Intervention type: DRUG
Intervention: Oxygen
Description: During and 2 hrs after surgery
Study NCT03828318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Activation Booklet and nursing support for patients with LARS
Description: The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
Study NCT02569827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celgosivir
Description: Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
Study NCT02569827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modipafant 50mg
Description: Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
Study NCT02569827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q6H for 5 days
Study NCT02569827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modipafant 100mg
Description: Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
Study NCT02425527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The rehabilitation gaming
Description: The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
Study NCT02425527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The entertaining gaming
Description: The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
Study NCT03894137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grains of Paradise (Aframomum Melegueta)
Description: This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
Study NCT03894137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grains of Paradise (Aframomum Melegueta)
Description: This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
Study NCT02062346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123
Description: Intravenous infusion of BQ123 ( selective ETA antagonist )
Study NCT02062346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ123/788
Description: or BQ123/788 (mixed ETA/B antagonists)
Study NCT02062346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline
Study NCT04872647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-Based Health Coaching Utilizing Lifestyle Action Plans
Description: Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
Study NCT00752115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 50mg, day1,8 and 15 in each cycle
Study NCT00752115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tab, day 1,8 and 15 in each cycle.
Study NCT01834378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity intervention
Description: We administer, a pedometer and the participants receive a prescription on physical exercise.
Study NCT01834378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity intervention.
Description: We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
Study NCT03400787 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Latera Implant
Description: Treatment with implant
Study NCT00752115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel (taxol)
Description: paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
Study NCT03400787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham procedure where the Latera delivery device is inserted but no implant delivered.
Study NCT00752115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel (taxol)
Description: paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
Study NCT00752115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin (palaplatin)
Description: carboplatin; AUC=6 on day 1, every 28 days
Study NCT00752115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin (palaplatin)
Description: carboplatin; AUC=6 on day 1, every 28 days
Study NCT02565927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional airway stent
Description: process airway stenting
Study NCT02565927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional airway stent
Description: process airway stenting
Study NCT06571604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dislocation
Description: One episode of total hip dislocation diagnozied on Xray within 2 years of surgery
Study NCT06571604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No dislocation
Description: No experience of dislocation within two years post-surgery
Study NCT03408808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Aspiration of ganglion and injection with platelet rich plasma.
Study NCT03408808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration alone
Description: Aspiration of the ganglion
Study NCT02920294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic 1
Description: Fresh fermented dairy drink containing yoghurt ferments
Study NCT02920294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic 2
Description: Fresh fermented dairy drink containing probiotic strain
Study NCT02920294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acidified dairy drink without ferments
Study NCT02451007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Study NCT03570385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
Study NCT02327143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally
Study NCT02327143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ¹³C₈-LY2835219
Description: Administered IV
Study NCT03224377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anti mutated citrullinated vimentin antibodies
Description: Blood sampling using ELisa technique
Study NCT00742690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terlipressin given by intravenous boluses and albumin
Description: Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
Study NCT00742690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terlipressin given by continuous intravenous infusion and albumin
Description: Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
Study NCT04105257 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: All patients
Description: Comparison of the results of the CTP with MRI
Study NCT01872182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-L1023
Description: daily twice for 12 weeks
Study NCT02565927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine-125 seeds
Description: process intraluminal brachytherapy
Study NCT01872182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily twice for 12 weeks
Study NCT00930800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Using a video game so-called Dance Dance Revolution (DDR)
Study NCT02674256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRH
Description: 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
Study NCT02674256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
Study NCT04082039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: convetional PCA method unsing only 1-channel
Description: Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
Study NCT04082039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: utilizing 2-channel
Description: Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
Study NCT00825851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: 15mg/16h + 10mg/16h to be used 24h
Study NCT00825851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Study NCT04869410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modification Broselow Tape
Description: Intubation using modified Broselow Tape prediction for predicting ETT size
Study NCT04869410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cole Formula
Description: Intubation using Cole Formula prediction for predicting ETT size
Study NCT02729012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline solution (NACL 3%+NAHCO3)
Description: Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
Study NCT02729012 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution (NACL 0,9%)
Description: Treatment with nebulized Saline Solution (NACL 0,9%)
Study NCT04147234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1387446
Description: intratumoral injection
Study NCT04147234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: intravenous infusion
Study NCT02682251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHR Messaging
Description: PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
Study NCT04348058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone recruitment to screening colonoscopy
Description: Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
Study NCT04348058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined methods recruitment to screening colonoscopy
Description: Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
Study NCT00638391 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Study NCT01266200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mantis
Description: percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
Study NCT01266200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: XIA
Description: Treatment of the fracture with Xia and conventional operation technique
Study NCT01507103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
Study NCT01507103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide (CPA)
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
Study NCT01507103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
Study NCT01507103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
Study NCT01485198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Autologous Stem Cells Infusion
Description: Extraction and knee infusion of Bone Marrow Autologous Stem Cells
Study NCT01485198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen (750mg orally TID) administration
Study NCT02773823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
Study NCT00825851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation
Study NCT00825851 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking cessation
Study NCT00825851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous smoking
Description: subjects smoke 20 cigarettes per day